Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.62 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.52 |
| ▸ | RXRG | P48443 | 2/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647092 | 0.87 | LRRK2 (0.65) | LRRK2SRPK3RXRARXRBRXRG | |
| SCHEMBL4435052 | 0.84 | RXRA (0.55) | LRRK2SRPK3RXRARXRBRXRG | |
| SCHEMBL2931922 | 0.82 | RXRA (0.47) | LRRK2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL1648521 | 0.82 | LRRK2 (0.56) | LRRK2PTGER1PTPN1KDM4ERAB9A | |
| SCHEMBL8239331 | 0.81 | LRRK2 (0.58) | LRRK2SRPK3RXRARXRBRXRG | |
| SCHEMBL5628371 | 0.81 | LRRK2 (0.58) | LRRK2SRPK3RXRARXRBRXRG | |
| SCHEMBL1647807 | 0.81 | MAOA (0.52) | LRRK2KDM4ERAB9AKMT2A | |
| SCHEMBL4422888 | 0.80 | RXRA (0.58) | LRRK2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL8243758 | 0.79 | LRRK2 (0.58) | LRRK2SRPK3RXRARXRBRXRG | |
| SCHEMBL1646547 | 0.79 | HTT (0.57) | LRRK2MRGPRX4KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483254-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2014-08-13 | — | — | EP | disclosed |
| US-8778939-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2483254-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184553-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| WO-2011038572-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184553-A1 | NOVEL COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885SRPK3 443/4885RXRA 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.